Fewer than one in 10 people that would benefit from obesity jabs like Wegovy are able to get them, states the WHO as it publishes its initial recommendations on the medications.
With in excess of 1,000,000,000 individuals worldwide now classified as obese, it is urging increased and just access to GLP-1 medication.
According to forecasts, over two billion will be obese by 2030 unless action is taken.
"The latest guidance affirms that obesity is a lifelong illness that can be addressed with thorough and continuous care," said its chief Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and distribution challenges are significant obstacles to widespread availability to the jabs that can help people shift substantial body mass, explains the agency.
GLP-1 Therapy Shortage
Despite the present most optimistic case, the production of GLP-1 therapies could only cover around 100 million people – fewer than 10% of eligible patients, as stated by the WHO.
The advice urges nations and manufacturers to widen availability, via strategies like patent sharing.
The intellectual property rights on the active ingredient – the primary component of Novo Nordisk's Wegovy – is scheduled to end in several nations in 2026.
How Weight-Loss Drugs Operate
GLP-1 drugs imitate a biological compound to delay gastric emptying, suppress the appetite and increase the sense of being full so individuals consume fewer calories.
People usually see weight reduction in the initial weeks of starting on the regular doses.
Studies indicates users may put most of the weight back on within a year of halting the treatment, because their typical food cravings come back.
To be overweight or obese elevates your chance for experiencing health problems, like diabetes, heart disease, stroke, and some cancers.
Excess weight concerns individuals in all nations and was linked to over three and a half million deaths worldwide in 2024, as per the WHO.
